• Room 02.005 - CCRCB

    United Kingdom

Accepting PhD Students

PhD projects

Dr Mullan's group is open to wide-ranging PhD applications from candidates with a basic science or clinical background. His fields of interest include: - Molecular Oncology - Cancer Biology and Signal Transduction - Drug discovery and development - Biomarkers, diagnosis and early detection of cancer Previous research experience is desirable although not essential.

20002020

Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Paul Mullan is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 66 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects

Research Output

Development of a novel allograft model of prostate cancer: a new tool to inform clinical translation

Haughey, C. M., Mukherjee, D., Steele, R. E., Popple, A., Dura-Perez, L., Pickard, A., Jain, S., Mullan, P. B., Williams, R., Oliveira, P., Buckley, N. E., Honeychurch, J., Williams, R., McDade, S., Illidge, T., Mills, I. G. & Eddie, S. L., 2020

Research output: Other contribution

Open Access
  • Open Access
  • Defining the molecular evolution of extrauterine high grade serous carcinoma

    Beirne, J. P., McArt, D. G., Roddy, A., McDermott, C., Ferris, J., Buckley, N. E., Coulter, P., McCabe, N., Eddie, S. L., Dunne, P. D., O'Reilly, P., Gilmore, A., Feeney, L., Ewing, D. L., Drapkin, R. I., Salto-Tellez, M., Kennedy, R. D., Harley, I. J. G., McCluggage, W. G. & Mullan, P. B., 04 Sep 2019, In : Gynecologic Oncology. 155, 2, p. 305-317 13 p.

    Research output: Contribution to journalArticle

  • Open Access
    File
  • 1 Citation (Scopus)
    95 Downloads (Pure)

    Identification and SAR exploration of a novel series of Legumain inhibitors

    Eddie, S. L., Gregson, A., Graham, E., Burton, S., Harrison, T., Burden, R., Scott, C. J., Mullan, P. B. & Williams, R., 15 Jun 2019, In : Bioorganic & Medicinal Chemistry Letters. 29, 12, p. 1546-1548 3 p.

    Research output: Contribution to journalArticle

  • Impact

    Development and Commercialization of a Technology Platform to Enable Biomarker Discovery and Validation

    Richard Kennedy (Participant), Paul Harkin (Participant), Patrick Johnston (Participant), Alison Hosey (Participant), Julia Miskelly (Participant), Margaret Murray (Participant), Jennifer Quinn (Participant), Colin James (Participant), Jude Mulligan (Participant), Peter Daly (Participant), Paul Mullan (Participant), Julie Mussen (Participant), Ultan McDermott (Participant), Richard Wilson (Participant), Daniel Longley (Participant)

    Impact: Health Impact, Quality of Life Impact